Nasdaq
$0.9637▲ 0.37%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $16.1MShares out 16.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 6d agoPre-market26.10.19 20:128-KKey event#●●●#●●●
Marker Therapeutics, Inc.Bullish
Marker Therapeutics has been awarded a $2.6 million grant from the FDA under the Orphan Products Clinical Trials program to support the Phase 1 clinical study of its lead investigational therapy, MT-601, for patients with pancreatic cancer. This non-dilutive funding recognizes the scientific rationale of the company's MAR-T cell platform, with clinical initiation for the pancreatic cancer program anticipated in the first quarter of 2027.…more
$0.9637+0.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 6d agoPre-market26.08.15 05:35filed10-QEarnings
Marker Therapeutics, Inc.
Marker Therapeutics reported a net loss of $1,826,229 for the second quarter of 2026. As of June 30, 2026, the company held $11,331,023 in cash and cash equivalents, with 16,673,127 shares of common stock outstanding as of August 7, 2026.…more
$0.9637+0.37%vs prev closeView filingShare - 6d agoPre-market26.05.16 06:00filed10-QEarnings
Marker Therapeutics, Inc.
Marker Therapeutics reported a net loss of $3,179,278 for the first quarter of 2026. As of March 31, 2026, the company held $14,915,519 in cash and cash equivalents, with 16,673,127 shares of common stock outstanding as of May 8, 2026.…more
$0.9637+0.37%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 20:00#●●●#●●●
Marker Therapeutics Secures $2.6M FDA Grant for Pancreatic Cancer Trial…more
Marker Therapeutics has been awarded a $2.6 million non-dilutive grant from the FDA to support a Phase 1 clinical trial of its MT-601 therapy for pancreatic cancer. While this funding validates the company's scientific platform, the project remains in early-stage development with no immediate revenue impact.…more
$0.9637+0.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUS